Piramal Pharma Limited (NSEI: PPLPHARMA)
Health Care · Pharmaceuticals · IN
Rs213.67
+3.40% today · +10.8% 1Y
Piramal Pharma Limited (NSEI: PPLPHARMA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.96B and employs 7,120 people.
Over the last twelve months the share price has gained 10.8%, trading between 132.30 and 220.36.
Tweenvest scores Piramal Pharma Limited across four factors: quality 53/100, value 34/100, growth 63/100. Its strongest factor is growth.
PPLPHARMA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.96B
- Revenue (TTM)
- $973.57M
- P/E
- —
- EPS
- -2.36
- Dividend yield
- —
- Beta (5Y)
- 0.32
- 52-week high
- Rs220.36
- 52-week low
- Rs132.30
- Avg volume (3M)
- —
- Shares outstanding
- 1.33B
- Employees
- 7,120
- Next earnings
- —
About Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids’ wellness, digestives, women’s health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.
- ISIN
- INE0DK501011
- Founded
- 2020
- Listed since
- Oct 19, 2022
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.